Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
59.70
+1.27 (2.17%)
At close: Apr 17, 2026, 4:00 PM EDT
60.00
+0.30 (0.50%)
After-hours: Apr 17, 2026, 6:57 PM EDT
Xenon Pharmaceuticals Revenue
In the year 2025, Xenon Pharmaceuticals had annual revenue of $7.50M.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
759.60
Revenue / Employee
$20,270
Employees
370
Market Cap
5.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.50M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.43M | -9.00M | -48.83% |
| Dec 31, 2021 | 18.44M | -13.73M | -42.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| CRISPR Therapeutics AG | 3.51M |
XENE News
- 4 days ago - Xenon to Present at Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting - GlobeNewsWire
- 5 weeks ago - Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 weeks ago - Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Xenon Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge - Benzinga
- 5 weeks ago - Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures - Benzinga
- 5 weeks ago - Xenon Pharma's epilepsy drug meets main goal in late-stage trial - Reuters